Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice

Adipocyte

Volumn 2, Issue 1, 2013, Pages 28-32

  Iwashita, Misaki ^a   Nakatsu, Yusuke ^a   Sakoda, Hideyuki ^b   Fujishiro, Midori ^b   Kushiyama, Akifumi ^c   Fukushima, Toshiaki ^a   Kumamoto, Sonoko ^a   Shinjo, Takanori ^a   Kamata, Hideaki ^a   Nishimura, Fusanori ^a   Asano, Tomoichiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

Adipocyte; ARB; Inflammation; Macrophage; Type 2 diabetes; Valsartan

Indexed keywords

CYTOKINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIVER; MACROPHAGE; METABOLIC SYNDROME X; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

MUS;

EID: 84904965332     PISSN: 21623945     EISSN: 2162397X     Source Type: Journal    
DOI: 10.4161/adip.21837     Document Type: Article

References (34)

1. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444:881-7; http://dx.doi.org/10.1038/nature05488
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-7; http://dx.doi.org/10.1038/nature05485
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444:840-6; http://dx.doi.org/10.1038/nature05482
4. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25:391-406; http://dx.doi.org/10.1146/annurev.nutr.24.012003.132155
5. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14:1225-30; http://dx.doi.org/10.2174/138161208784246153
6. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72:219-46; http://dx.doi.org/10.1146/annurev-physiol-021909-135846
7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr.. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-808;
8. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-30
9. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-72; http://dx.doi.org/10.2337/db06-1491
10. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-3; http://dx.doi.org/10.1038/4441022a
11. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, et al. Loss-offunction mutation in Toll-like receptor 4 prevents dietinduced obesity and insulin resistance. Diabetes 2007; 56:1986-98; http://dx.doi.org/10.2337/db06-1595
12. Galletti F, Strazzullo P, Capaldo B, Carretta R, Fabris F, Ferrara LA, et al. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 1999; 17:439-45; http://dx.doi.org/10.1097/00004872-199917030-00018
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62; http://dx.doi.org/10.1056/NEJM199311113292004
14. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, PravenecM, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43:993-1002; http://dx.doi.org/10.1161/01.HYP.0000123072.34629.57
15. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factoralpha. Hypertens Res 2006; 29:849-56; http://dx.doi.org/10.1291/hypres.29.849
16. Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med 2006; 119(Suppl 1):S24-30; http://dx.doi.org/10.1016/j.amjmed.2006.01.011
17. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43:1003-10; http://dx.doi.org/10.1161/01.HYP.0000125142.41703.64
18. Bernlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly TJ, Jr.. Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci U S A 1984; 81:5468-72; http://dx.doi.org/10.1073/pnas.81.17.5468
19. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, et al. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006; 45:154-62; http://dx.doi.org/10.1016/j.vph.2006.05.002
20. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-c activity. Circulation 2004; 109:2054-7; http://dx.doi.org/10.1161/01.CIR.0000127955.36250.65
21. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor c (PPAR c). J Biol Chem 1995; 270:12953-6; http://dx.doi.org/10.1074/jbc.270.22.12953
22. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, et al. PPAR c 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007; 3: e64; http://dx.doi.org/10.1371/journal.pgen.0030064
23. Spiegelman BM. PPAR-c: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-14; http://dx.doi.org/10.2337/diabetes.47.4.507
24. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-90; http://dx.doi.org/10.1056/NEJMoa1001121
25. Iwashita M, Sakoda H, Kushiyama A, Fujishiro M, Ohno H, Nakatsu Y, et al. Valsartan, independently of AT1 receptor or PPARc, LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. Am J Physiol Endocrinol Metab 2012; 302:E286-96; http://dx.doi.org/10.1152/ajpendo.00324.2011
26. Kumamoto S, Kushiyama A, Nakatsu Y, Sakoda H, Fujishiro M, Iwashita M, et al. Angiotensin receptor 1 blocker valsartan normalizes gene expression profiles of 3T3-L1 adipocytes altered by co-culture with LPStreated RAW264.7 macrophages. Obes Res Clin Pract 2012; 6:e9-e20; http://dx.doi.org/10.1016/j.orcp.2012.05.005
27. Lanthier N, Molendi-Coste O, Horsmans Y, van Rooijen N, Cani PD, Leclercq IA. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010; 298: G107-16; http://dx.doi.org/10.1152/ajpgi.00391.2009
28. Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Büschenfelde KH, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol 1995; 22:226-9; http://dx.doi.org/10.1016/0168-8278(95)80433-1
29. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007; 47:142-56; http://dx.doi.org/10.1016/j.jhep.2007.04.002
30. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45:1375-81; http://dx.doi.org/10.1002/hep.21638
31. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54:133-44; http://dx.doi.org/10.1002/hep.24341
32. Sawada T, Yamada H, Dahlöf B, Matsubara H, KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; 30:2461-9; http://dx.doi.org/10.1093/eurheartj/ehp363
33. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:3349-54; http://dx.doi.org/10.1210/jc.2005-2226
34. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30:1574-6; http://dx.doi.org/10.2337/dc06-2606